Belantamab mafodotin
- Generic Name
- Belantamab mafodotin
- Brand Names
- BLENREP
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2050232-20-5
- Unique Ingredient Identifier
- DB1041CXDG
- Background
Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
...
- Indication
Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Associated Therapies
- -
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Conditions
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 520
- Registration Number
- NCT06679101
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
- Conditions
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT06655818
- Locations
- ๐ฐ๐ท
GSK Investigational Site, Ulsan, Korea, Republic of
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT06160609
- Locations
- ๐ธ๐ช
GSK Investigational Site, Stockholm, Sweden
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Duke University
- Target Recruit Count
- 30
- Registration Number
- NCT05986682
- Locations
- ๐บ๐ธ
Duke University Medical Center, Durham, North Carolina, United States
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05922501
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Cristiana Costa Chase, DO
- Target Recruit Count
- 33
- Registration Number
- NCT05874193
- Locations
- ๐บ๐ธ
Johnston Cancer Center, Smithfield, North Carolina, United States
๐บ๐ธUNC Health Southeastern, Lumberton, North Carolina, United States
๐บ๐ธJohnston Hematology and Oncology of Clayton, Clayton, North Carolina, United States
Corneal Findings in Patients Treated With Belantamab Mafodotin
- Conditions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 50
- Registration Number
- NCT05833737
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 83
- Registration Number
- NCT05789303
- Locations
- ๐บ๐ธ
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT05714839
- Locations
- ๐ฌ๐ง
GSK Investigational Site, Plymouth, United Kingdom
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 48
- Registration Number
- NCT05581875
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.